Edit search
An adjuvant autologous therapeutic vaccine %28HSPPC-96%3B vi…
An adjuvant autologous therapeutic vaccine %28HSPPC-96%3B vitespen%29 versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma%3A a multicentre%2C open-label%2C randomised phase III trial.
An adjuvant autologous therapeutic vaccine %28HSPPC-96%3B vitespen%29 versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma%3A a multicentre%2C open-label%2C randomised phase III trial.
Article, Chapter
Authors: C. Wood
Publication: Lancet, The, Volume:372, Issue:9633
Published: Elsevier, 2008
ISSN: 0140-6736
  Full text availability for this item
Browse related articles
  Print copies at your library
  Request a copy of this item
Cite this item